US 12,286,452 B2
Amphiphilic aminoglycoside connexin hemichannel inhibitors
Guillermo A. Altenberg, Lubbock, TX (US); and Cheng-Wei Tom Chang, Logan, UT (US)
Assigned to TEXAS TECH UNIVERSITY SYSTEM, Lubbock, TX (US); and UTAH STATE UNIVERSITY, Logan, UT (US)
Filed by Texas Tech University System, Lubbock, TX (US); and Utah University, Logan, UT (US)
Filed on Dec. 11, 2020, as Appl. No. 17/119,301.
Application 17/119,301 is a continuation in part of application No. PCT/US2019/036714, filed on Jun. 12, 2019.
Claims priority of provisional application 62/683,673, filed on Jun. 12, 2018.
Prior Publication US 2021/0163521 A1, Jun. 3, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 15/234 (2006.01)
CPC C07H 15/234 (2013.01) 5 Claims
 
1. An amphiphilic molecule with a structure

OG Complex Work Unit Chemistry
having reduced antimicrobial activity when compared to unmodified kanamycin; wherein
Y is H2,
Z is HR4,
R1, R2, R3, R4 are, methyl, ethyl, propyl, butyl, linear alkyl, alkylcarbonyl chains, or cyclic groups.